T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$1.6B |
| 2 |
Verizon
VZ
|
+$1.3B |
| 3 |
US Bancorp
USB
|
+$1.26B |
| 4 |
Berkshire Hathaway Class B
BRK.B
|
+$1.26B |
| 5 |
Lam Research
LRCX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$6.33B |
| 2 |
Tesla
TSLA
|
+$5.64B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$4.91B |
| 4 |
TMX
Terminix Global Holdings, Inc.
TMX
|
+$3.44B |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.4B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.7% |
| 2 | Healthcare | 19.64% |
| 3 | Financials | 12.71% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Communication Services | 7.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2801
Cardiff Oncology
CRDF
$80.9M
| $51K | ﹤0.01% |
36,500
| – | – |
|
2802
Innodata
INOD
$2.05B
| $51K | ﹤0.01% |
17,300
| – | – |
|
2803
Ovid Therapeutics
OVID
$521M
| $51K | ﹤0.01% |
27,500
| – | – |
|
2804
OmniAb
OABI
$503M
| $49K | ﹤0.01% |
+13,510
| New | +$70.9K |
|
|
SLGCW
2805
DELISTED
SomaLogic, Inc. Warrant
SLGCW
| $49K | ﹤0.01% |
123,236
-6,989
| -5% | -$2.78K |
|
|
TCRR
2806
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $49K | ﹤0.01% |
48,900
+14,700
| +43% | +$19.8K |
|
2807
Blend Labs
BLND
$357M
| $48K | ﹤0.01% |
33,248
+4,585
| +16% | +$8.22K |
|
2808
Lantronix
LTRX
$275M
| $48K | ﹤0.01% |
11,200
| – | – |
|
|
LOGC
2809
DELISTED
ContextLogic
LOGC
| $48K | ﹤0.01% |
3,270
+300
| +10% | +$6.17K |
|
|
SRT
2810
DELISTED
Startek Inc.
SRT
| $48K | ﹤0.01% |
12,800
| – | – |
|
2811
Arbutus Biopharma
ABUS
$898M
| $47K | ﹤0.01% |
20,049
+1,974
| +11% | +$4.72K |
|
2812
Vroom Inc
VRM
$51.2M
| $47K | ﹤0.01% |
570
-161
| -22% | -$13.8K |
|
2813
Aveanna Healthcare
AVAH
$2.44B
| $46K | ﹤0.01% |
59,518
| – | – |
|
2814
Archer Aviation
ACHR
$5.36B
| $45K | ﹤0.01% |
24,177
+1,894
| +8% | +$4.67K |
|
2815
Erasca
ERAS
$6.34B
| $45K | ﹤0.01% |
10,516
+470
| +5% | +$3.19K |
|
|
KG
2816
Kestrel Group
KG
$61.8M
| $45K | ﹤0.01% |
1,065
| – | – |
|
2817
Energy Vault
NRGV
$687M
| $45K | ﹤0.01% |
+14,503
| New | +$53.8K |
|
2818
Savara
SVRA
$1.11B
| $45K | ﹤0.01% |
28,960
| – | – |
|
2819
Shattuck Labs
STTK
$741M
| $44K | ﹤0.01% |
19,300
| – | – |
|
|
SYRS
2820
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $44K | ﹤0.01% |
+12,150
| New | +$52.7K |
|
2821
AEye
LIDR
$60.4M
| $43K | ﹤0.01% |
3,017
+2,220
| +279% | +$57.6K |
|
|
AIOT
2822
PowerFleet Inc
AIOT
$417M
| $43K | ﹤0.01% |
15,900
| – | – |
|
|
DBD
2823
DELISTED
Diebold Nixdorf Incorporated
DBD
| $43K | ﹤0.01% |
30,093
-29,800
| -50% | -$63.9K |
|
2824
MediciNova
MNOV
$64.5M
| $42K | ﹤0.01% |
20,700
| – | – |
|
2825
Smartbird Inc
BIRD
$30.2M
| $41K | ﹤0.01% |
847
+99
| +13% | +$5.8K |
|
Similar funds
T. Rowe Price Associates's Q4 2022 Portfolio in Review
As of Q4 2022, T. Rowe Price Associates held 3,066 positions worth $622B, up 1.8% from $610B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
T. Rowe Price Associates's Q4 2022 filing shows 113 new, 1,569 increased, 1,081 reduced and 107 closed positions. Its largest new stake was GE HealthCare: 6,360,001 shares worth $371M. The largest sale was Amazon, an estimated $6.33B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 26% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q4 2022 buy was GE HealthCare: 6,360,001 shares worth $371M.
- T. Rowe Price Associates added most to JPMorgan Chase in Q4 2022, an estimated $1.6B increase.
- T. Rowe Price Associates's biggest Q4 2022 reduction was Amazon, cutting an estimated $6.33B.
- T. Rowe Price Associates fully exited Terminix Global Holdings, Inc. in Q4 2022, selling an estimated $3.44B.
- T. Rowe Price Associates's ten largest holdings make up 27% of its $622B portfolio in Q4 2022.
- T. Rowe Price Associates opened 113 new positions and closed 107 in Q4 2022.
- T. Rowe Price Associates's portfolio value rose 1.8% quarter-over-quarter to $622B.
Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.